Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.

Autor: Conte P; DiSCOG, University of Padova and Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy., Schneeweiss A; National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany., Loibl S; GBG, Neu-Isenburg, Germany.; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany., Mamounas EP; NSABP Foundation and Orlando Health University of Florida Health Cancer Center, Orlando, Florida., von Minckwitz G; GBG, Neu-Isenburg, Germany., Mano MS; Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Untch M; AGO-B and HELIOS Klinikum Berlin Buch, Berlin, Germany., Huang CS; National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Wolmark N; NSABP Foundation and University of Pittsburgh, Pittsburgh, Pennsylvania., Rastogi P; NSABP Foundation and University of Pittsburgh, Pittsburgh, Pennsylvania., D'Hondt V; Institut Régional du Cancer de Montpellier, Montpellier, France., Redondo A; Hospital Universitario La Paz-IdiPAZ, Madrid, Spain., Stamatovic L; Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Bonnefoi H; Institut Bergonié Unicancer and Bordeaux University, Bordeaux, France., Castro-Salguero H; Grupo Medico Angeles, Guatemala City, Guatemala., Fischer HH; GBG and Evangelische Kliniken Gelsenkirchen, Gelsenkirchen, Germany., Wahl T; Swedish Cancer Institute, Issaquah, Washington., Song C; Genentech, Inc., South San Francisco, California., Boulet T; F. Hoffmann-La Roche, Basel, Switzerland., Trask P; Genentech, Inc., South San Francisco, California., Geyer CE Jr; NSABP Foundation and Houston Methodist Cancer Center, Houston, Texas.

Publikováno v: Cancer [Cancer] 2020 Jul 01; Vol. 126 (13), pp. 3132-3139. Date of Electronic Publication: 2020 Apr 14.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer.

Autor: YUTARO KUBOTA, KIYOSHI YOSHIMURA, KAZUYUKI HAMADA, YUYA HIRASAWA, MIDORI SHIDA, MAKOTO TANIGUCHI, HIROTO MATSUI, HIROTSUGU ARIIZUMI, TOMOYUKI ISHIGURO, NORIHIRO SUZUKI, RYOTARO OHKUMA, TAKEHIKO SAMBE, HIROO ISHIDA, ATSUSHI HORIIKE, SATOSHI WADA, JUNJI TSURUTANI, SANJU IWAMOTO, NAOKI UCHIDA, YUJI KIUCHI, SHINICHI KOBAYASHI

Publikováno v: In Vivo; May/Jun2021, Vol. 35 Issue 3, p1865-1875, 11p

Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN).

Autor: Fornaro, Lorenzo¹ (AUTHOR) lorenzo.fornaro@gmail.com, Spallanzani, Andrea² (AUTHOR) andrea.spallanzani@gmail.com, de Vita, Ferdinando³ (AUTHOR) ferdinando.devita@unicampania.it, D'Ugo, Domenico⁴ (AUTHOR) domenicodugo@icloud.com, Falcone, Alfredo⁵ (AUTHOR) alfredo.falcone@med.unipi.it, Lorenzon, Laura⁴ (AUTHOR) laura.lorenzon@policlinicogemelli.it, Tirino, Giuseppe³ (AUTHOR) giuseppe.tirino@unicampania.it, Cascinu, Stefano⁶ (AUTHOR) cascinu.stefano@hsr.it, van Berge Henegouwen, Mark (AUTHOR)

Publikováno v: Cancers. Mar2021, Vol. 13 Issue 6, p1304. 1p.